Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients.

The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.
NSCLC
DRUG: Apatinib Mesylate, Gefitinib
Cmax, Maximum Observed Plasma Concentration for apatinib, 0-24 hours|AUC0-Ï„, Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 hours, 0-24 hours
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients.

The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.